Abstract:Background Systemic sclerosis (SSc) is an autoimmune disease characterized with multiple organ fibrosis. Previous studies showed transcription factor early growth response 1 (Egr1) overexpressed in the lesional skin of SSc patients, as well as Egr1 inducible genes1. Egr1 forms a positive feedback loop with master pro-fibrotic cytokine TGF and thus promotes fibrosis. Objectives To investigate the anti-fibrotic effect of a novel DMARD iguratimod in scleroderma models and patient skin grafts. Methods We used iguratimod to treat TGF-stimulated human skin fibroblast, bleomycin induced mice, tight skin 1 (TSK-1) mice and SSc skin grafts. The bleomycin model contained pre-establish fibrosis and late onset treatment. The skin grafts came from three SSc patients and was planted into irradiated nude mice. Results Iguratimod down-regulated egr1 expression in human skin fibroblast, with decreased collagen production and a-SMA expression. Knocking down Egr1 in fibroblast could mimic these effects. Both oral and topical iguratimod could reduce dermal thickening and collagen deposition in bleomycin induced skin fibrosis. a-SMA (+) myofibroblast counts, as well as Egr1 (+) and/or TGF (+) fibroblast counts in iguratimod treated groups were significantly less than the controls. Similarly, topical iguratimod ameliorated fibrosis with deduced dermal thickening in TSK-1 mice. Of note, 5-week iguratimod local injection remarkably reduced collagen content in skin grafts from three SSc patients. Staining of Egr1 and TGF in skin tissue were inhibited after iguratimod treatment simultaneously. Conclusion We found the potential of iguratimod to treat SSc, which was characterized as an Egr1 inhibitor. Further clinical investigation is needed to establish its safety and efficacy. References [1] Bhattacharyya S, Sargent JL, Du P, et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PloS one 2011;6(9):e23082 doi: 10.1371/journal.pone.0023082 [2] Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. The Journal of biological chemistry 2006;281(30):21183-97 doi: 10.1074/jbc.M603270200 [2] Wu M, Melichian DS, de la Garza M, et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. The American journal of pathology 2009;175(3):1041-55 doi: 10.2353/ajpath.2009. Acknowledgement This work is supported by National Natural Science Foundation of China (81601401). Disclosure of Interests None declared

Iguratimod Attenuated Fibrosis in Systemic Sclerosis Via Targeting Early Growth Response 1 Expression.

Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes

THU0355 IGURATIMOD MIGHT TREAT SCLERODERMA WITH INTERRUPTED EGR1/TGF-? LOOP

Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis

Iguratimod Suppresses Plasma Cell Differentiation and Ameliorates Experimental Sjögren’s Syndrome in Mice by Promoting TEC Kinase Degradation

Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjögren's syndrome in mice by promoting TEC kinase degradation

Iguratimod Represses B Cell Terminal Differentiation Linked with the Inhibition of PKC/EGR1 Axis.

Inhibition of the Hedgehog Pathway Leads to Antifibrotic Effects in Dermal Fibrosis

A Novel DMARD, Iguratimod Disrupts TGF-b Signaling in Epithelial Cells and Attenuates Bleomycin-Induced Interstitial Lung Disease in Mice

Smad-Independent Transforming Growth Factor-β Regulation of Early Growth Response-1 and Sustained Expression in Fibrosis

Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials

The efficacy and mechanism for action of iguratimod in primary Sjögren’s syndrome patients

Iguratimod Inhibits Renal Interstitial Fibrosis in Lupus Nephritis

MiR-3606-3p Inhibits Systemic Sclerosis Through Targeting TGF-β Type II Receptor

Efficacy and Safety of Iguratimod on Patients with Primary Sjögren's Syndrome: a Randomized, Placebo-Controlled Clinical Trial.

Isoform-selective TGF-β3 inhibition for systemic sclerosis

Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition

Iguratimod Treatment Reduces Disease Activity in Early Primary Sjögren's Syndrome: an Open-Label Pilot Study.

Clinical Efficacy and Immunoregulation Effects of Iguratimod on Th Subsets in Patients with Rheumatoid Arthritis

Clinical study of effectiveness and safety of Iguratimod in treating primary Sj(o)gren's syndrome

Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis